FAQ

Abnormal involuntary movement

Known as: Abnormal involuntary movements 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-2017
05101519752017

Related topics

Related topics

26 relations

Narrower (9)

Abnormal head movementsAthetosisChoreaChoreoathetosis
(More)
BradykinesiaCerebral PalsyCongenital Cerebral PalsyEpisodic Kinesigenic Dyskinesia 2
(More)

Broader (5)

Brain DiseasesDyskinetic syndromeMovement Disordersmusculoskeletal symptom
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Abnormal involuntary movement
nervous system disorder
Gilles de la Tourette syndrome
Brain Diseases
Tremor
Cerebral Palsy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy for Parkinson's disease (PD). Unfortunately… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
L-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of Parkinson's Disease. A model of LID has… (More)
Is this relevant?
2007
2007
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
L-DOPA-induced motor complications can be modelled in rats with 6-hydroxydopamine (6-OHDA) lesions by chronic injections of L… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
We explored possible differences in the peripheral and central pharmacokinetics of L-DOPA as a basis for individual variation in… (More)
Is this relevant?
2006
2006
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Intrastriatal transplants of embryonic ventral mesencephalon can cause dyskinesia in patients with Parkinson's disease (PD). We… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.
We have examined the pattern of striatal messenger RNA expression of over 8000 genes in a rat model of levodopa (L-DOPA)-induced… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
In order to assess the role of striatal dopamine (DA) afferents in L-DOPA-induced dyskinesia, we have studied a large series of… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
In an attempt to define clinically relevant models of akinesia and dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, we… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.
We investigated the role of dopamine neurons in the manifestation of levodopa-induced dyskinesia in a rat model of Parkinson's… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1996
1996
Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients.
Chronic electrical subthalamic nucleus (STN) stimulation is under investigation for alleviating parkinsonian symptoms. STN… (More)
Is this relevant?